About: Antiviral Strategies of Chinese Herbal Medicine Against PRRSV Infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Antiviral Strategies of Chinese Herbal Medicine Against PRRSV Infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Antiviral Strategies of Chinese Herbal Medicine Against PRRSV Infection
Creator	Li, Yanhua Wang, Gang Cai, Xuehui Zhang, Yu Yu, Fei Zhang, Bo Tramontano, Enzo Han, Xiao Cn, Caixuehui@caas Cui, Wenqiang God'spower Bello-Onaghise, Li, Zhengze Nsabimana, Eliphaz Wang, Linguang Zhang, Yuefeng
Source	Medline; PMC
abstract	Bioactive compounds from Traditional Chinese Medicines (TCMs) are gradually becoming an effective alternative in the control of porcine reproductive and respiratory syndrome virus (PRRSV) because most of the commercially available PRRSV vaccines cannot provide full protection against the genetically diverse strains isolated from farms. Besides, the incomplete attenuation procedure involved in the production of modified live vaccines (MLV) may cause them to revert to the more virulence forms. TCMs have shown some promising potentials in bridging this gap. Several investigations have revealed that herbal extracts from TCMs contain molecules with significant antiviral activities against the various stages of the life cycle of PRRSV, and they do this through different mechanisms. They either block PRRSV attachment and entry into cells or inhibits the replication of viral RNA or viral particles assembly and release or act as immunomodulators and pathogenic pathway inhibitors through cytokines regulations. Here, we summarized the various antiviral strategies employed by some TCMs against the different stages of the life cycle of PRRSV under two major classes, including direct-acting antivirals (DAAs) and indirect-acting antivirals (IAAs). We highlighted their mechanisms of action. In conclusion, we recommended that in making plans for the use of TCMs to control PRRSV, the pathway forward must be built on a real understanding of the mechanisms by which bioactive compounds exert their effects. This will provide a template that will guide the focus of collaborative studies among researchers in the areas of bioinformatics, chemistry, and proteomics. Furthermore, available data and procedures to support the efficacy, safety, and quality control levels of TCMs should be well documented without any breach of data integrity and good manufacturing practices.
has issue date	2020-07-28(xsd:dateTime)
bibo:doi	10.3389/fmicb.2020.01756
bibo:pmid	32849384
has license	cc-by
sha1sum (hex)	47cf42d2faa9110fd4255f3593c52fabcca4105a
schema:url	https://doi.org/10.3389/fmicb.2020.01756
resource representing a document's title	Antiviral Strategies of Chinese Herbal Medicine Against PRRSV Infection
has PubMed Central identifier	PMC7401453
has PubMed identifier	32849384
schema:publication	Front Microbiol
resource representing a document's body	covid:47cf42d2faa9110fd4255f3593c52fabcca4105a#body_text
is schema:about of	named entity 'Antiviral' named entity 'IL-8' named entity 'Interleukin-10' named entity 'endocytic pathway' named entity 'myosin heavy chain' named entity 'TNF' named entity 'virus' named entity 'anti-oxidant' named entity 'aglycone' named entity 'MyD88' named entity 'KPNA1' named entity 'matrine' named entity 'RNA' named entity 'Traditional Chinese' named entity 'heparanase' named entity 'interleukin-1' named entity 'immunomodulators' named entity 'replicase' named entity 'PRRSV' named entity 'RNA' named entity 'acute inflammatory response' named entity 'TLR4' named entity 'IL-6' named entity 'cytokines' named entity 'antiemetic' named entity 'Protein' named entity 'IFN' named entity 'adaptive immune responses' named entity 'good manufacturing practices' named entity 'intracellular transport' named entity 'cell membrane' named entity 'PRRSV' named entity 'Nsp2' named entity 'infection' named entity 'RNA-dependent RNA polymerase' named entity 'antiviral' named entity 'transcription factor' named entity 'downregulating' named entity 'infection' named entity 'China' named entity 'host defense mechanisms' named entity 'glycan' named entity 'host defense' named entity 'TNF' named entity 'viremia' named entity 'MLV' named entity 'Chinese traditional herbal medicine' named entity 'bioactive compound' named entity 'HCV' named entity 'tumor necrosis factor' named entity 'antigen' named entity 'protein' named entity 'global outbreak' named entity 'cell surface' named entity 'PRRSV' named entity 'IFNα' named entity 'hippocampus' named entity 'inflammatory cytokine' named entity 'Chlorogenic acid' named entity 'alveolar' named entity 'life cycle' named entity 'IL-6' named entity 'IL-6' named entity 'inflammatory process' named entity 'NF-κB' named entity 'nucleocapsid' named entity 'PRRSV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software